7.2 Strong P-glycoprotein (P-gp) Inhibitors 7.3 Alpha-Blockers 7.4 Digoxin 7.5 PDE5 Inhibitors 7.6 Other Concomitant Drug ... P-glycoprotein (P-gp) Inhibitors In vitro studies indicated that silodosin is a P-gp substrate. A drug interaction study with a ... 7.2 Strong P-glycoprotein (P-gp) Inhibitors. In vitro studies indicated that silodosin is a P-gp substrate. Ketoconazole, a ... Strong P-glycoprotein inhibitors (e.g., cyclosporine): Co-administration may increase plasma silodosin concentration. ...

7.1 Inducers of P-glycoprotein or CYP3A4 Enzymes 7.2 Insulin Secretagogues or Insulin 8 USE IN SPECIFIC POPULATIONS 8.1 ... Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with ... Linagliptin is a P-glycoprotein (P-gp) substrate, and inhibits P-gp mediated transport of digoxin at high concentrations. Based ... 7.1 Inducers of P-glycoprotein or CYP3A4 Enzymes. Rifampin decreased linagliptin exposure, suggesting that the efficacy of ...

P-glycoprotein Inducers Increase GILOTRIF daily dose by 10 mg as tolerated for patients who require chronic therapy with a P-gp ... P-glycoprotein Inhibitors Reduce GILOTRIF daily dose by 10 mg if not tolerated for patients who require therapy with a P- ... Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ... P-glycoprotein (P-gp) Inhibitors: Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce GILOTRIF by 10 mg ...

P-glycoprotein (e.g. Digoxin) - Coadministration of tadalafil (40 mg once per day) for 10 days did not have a significant ...

Transporter Systems: Ripretinib is an inhibitor of P-gp (P-glycoprotein) and BCRP (Breast Cancer Resistance Protein). DP-5439 ...

... and/or P-glycoprotein (except narrow therapeutic index drugs, e.g., digoxin), when vilazodone hydrochloride is administered ...

P-glycoprotein (P-gp) Substrates. Clinical Impact. *Co-administration of BALVERSA with P-gp substrates may increase the plasma ... Erdafitinib protein binding was 99.8% in patients, primarily to alpha-1-acid glycoprotein. ...

P-glycoprotein substrates: EMEND is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as ... Aprepitant is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter. ...

P-glycoprotein (e.g. Digoxin) - Coadministration of tadalafil (40 mg once per day) for 10 days did not have a significant ...

Ranolazine is also a substrate of P-glycoprotein.. Strong CYP3A Inhibitors Plasma levels of ranolazine with RANEXA 1000 mg ...

Inhibitory Effect of Pirfenidone on P-glycoprotein (Pgp) The potential for pirfenidone to inhibit Pgp mediated transport of ...

Metoprolol is not a significant P-glycoprotein substrate.. Metabolism Metoprolol is primarily metabolized by CYP2D6. Metoprolol ...

Inhibitory Effect of Pirfenidone on P-glycoprotein (Pgp) The potential for pirfenidone to inhibit Pgp mediated transport of ...

Metoprolol is not a significant P-glycoprotein substrate.. Elimination Elimination of metoprolol is mainly by biotransformation ...

P-glycoprotein (P-gp) Substrates: Coadministration of RETEVMO with dabigatran (P-gp substrate) increased the dabigatran AUC0- ...

P-Glycoprotein (P-gp) Inhibitors. Clinical Impact:. The concomitant use of PGP-inhibitors can increase the exposure to morphine ...

Transporter Systems: Azacitidine is not a substrate of P-glycoprotein (P-gp). Azacitidine does not inhibit P-gp, breast cancer ...

In plasma, risperidone is bound to albumin and α1-acid glycoprotein. The plasma protein binding of risperidone is 90%, and that ... because of the diminished concentration of both albumin and α1-acid glycoprotein. Risperidone doses should be reduced in ...

In plasma, risperidone is bound to albumin and α 1-acid glycoprotein. The plasma protein binding of risperidone is ... 1-acid glycoprotein. RISPERDAL ® doses should be reduced in patients with liver disease [see Dosage and Administration (2.4)] ...

In plasma, risperidone is bound to albumin and α 1-acid glycoprotein. The plasma protein binding of risperidone is ... 1-acid glycoprotein. Risperidone tablets doses should be reduced in patients with liver disease [see Dosage and Administration ...

Colchicine is a substrate of the efflux transporter P-glycoprotein (P-gp). Of the cytochrome P450 enzymes tested, CYP3A4 was ... Coadministration of colchicine with drugs known to inhibit CYP3A4 and/or P-glycoprotein (P-gp) increases the risk of colchicine ...

Bendamustine is a substrate of P-glycoprotein and breast cancer resistance protein (BCRP). ...

Binding is also dependent on the plasma concentration of the alpha-l- acid glycoprotein. ...

Binding is also dependent on the plasma concentration of the alpha-1-acid glycoprotein. Lidocaine HCl crosses the blood-brain ...

Binding is also dependent on the plasma concentration of the alpha-1-acid glycoprotein. ...

An in vitro study indicates that ropinirole is not a substrate for P-glycoprotein. Ropinirole and its circulating metabolites ...

An in vitro study showed that donepezil was not a substrate of P-glycoprotein. Drugs Highly Bound to Plasma Proteins Drug ... Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha1 - acid glycoprotein ( ...

Gabapentin enacarbil is neither a substrate nor an inhibitor of P-glycoprotein in vitro. ... Gabapentin enacarbil is neither a substrate nor an inhibitor of P-glycoprotein in vitro. ...

Darifenacin is approximately 98% bound to plasma proteins (primarily to alpha-1-acid-glycoprotein). The steady-state volume of ...